Binimetinib, sold under the brand name Mektovi, is an
anti-cancer medication used to treat various cancers.[3] Binimetinib is a selective inhibitor of MEK, a central
kinase in the tumor-promoting
MAPK pathway.[4] Inappropriate activation of the pathway has been shown to occur in many cancers.[4] In June 2018 it was approved by the FDA in combination with
encorafenib for the treatment of patients with unresectable or metastatic BRAF
V600E or V600K mutation-positive melanoma.[5][6] In October 2023, it was approved by the FDA for treatment of NSCLC with a
BRAF V600E mutation in combination with
encorafenib.[7] It was developed by
Array Biopharma.
Mechanism of action
Binimetinib is an orally available inhibitor of mitogen-activated protein kinase kinase (MEK), or more specifically, a
MAP2K inhibitor.[8] MEK is part of the
RAS pathway, which is involved in cell proliferation and survival. MEK is upregulated in many forms of cancer.[9] Binimetinib, uncompetitive with ATP, binds to and inhibits the activity of MEK1/2 kinase, which has been shown to regulate several key cellular activities including proliferation, survival, and angiogenesis.[10] MEK1/2 are
dual-specificity threonine/tyrosine kinases that play key roles in the activation of the RAS/RAF/MEK/ERK pathway and are often upregulated in a variety of tumor cell types.[11] Inhibition of MEK1/2 prevents the activation of MEK1/2 dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling.[12] As demonstrated in preclinical studies, this may eventually lead to an inhibition of tumor cell proliferation and an inhibition in production of various inflammatory cytokines including
interleukin-1,
-6 and
tumor necrosis factor.[12]
In December 2015, the company announced that the mutant-NRAS melanoma trial was successful.[16] In the trial, those receiving binimetinib had a median
progression-free survival of 2.8 months versus 1.5 months for those on the standard
dacarbazine treatment.[17]NDA submitted Jun 2016,[18] and the FDA should decide by 30 June 2017.[19]
In April 2016, it was reported that the phase III trial for low-grade ovarian cancer was terminated due to lack of efficacy.[20]
In 2017, the FDA informed Array Biopharma that the phase III trial data was not sufficient and the
New Drug Application was withdrawn.[21]
In June 2018, it was approved for the treatment of certain melanomas by the U.S.
Food and Drug Administration (FDA) in combination with encorafenib.[5] The FDA approved binimetinib based primarily on evidence from one clinical trial (NCT01909453) of 383 patients with BRAF V600 mutation-positive melanoma that was advanced or could not be removed by surgery.[6] The trial was conducted at 162 sites in Europe, North America, and various countries around the world.[6]
^Ascierto PA, Schadendorf D, Berking C, et al. (March 2013). "MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study". The Lancet. Oncology. 14 (3): 249–56.
doi:
10.1016/S1470-2045(13)70024-X.
PMID23414587.
^Mehdizadeh A, Somi MH, Darabi M, et al. (February 2016). "Extracellular signal-regulated kinase 1 and 2 in cancer therapy: a focus on hepatocellular carcinoma". Molecular Biology Reports. 43 (2): 107–16.
doi:
10.1007/s11033-016-3943-9.
PMID26767647.
S2CID15113957.
^Clinical trial number NCT01849874 for "A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer" at
ClinicalTrials.gov
^Clinical trial number NCT01909453 for "Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma (COLUMBUS)" at
ClinicalTrials.gov
^Clinical trial number NCT01763164 for "Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma" at
ClinicalTrials.gov